Blue test tubes arranged in a line, disappearing into the background

News

Complete Response Letter for ND 0612 for treatment of motor fluctuations in people with Parkinson’s disease

Read time: 1 mins

Published:14th Jun 2024

Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, announced that the FDA has issued a Complete Response Letter for the New Drug Application (NDA) of investigational ND 0612 for the treatment of motor fluctuations in people with Parkinson’s disease which is being developed by its wholly owned subsidiary, NeuroDerm Ltd. is currently reviewing the CRL and will work closely with the FDA to address its comments to consider the future direction

Condition: Parkinsons

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

NICE (UK) positive for Fabhalta (iptacopan) to treat paroxysmal nocturnal haemoglobinuria

Iptacopan is recommended, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia. Iptacopan is only recommended if the company provides it according to the commercial arrangement

1 mins

Drug news

NICE (UK) positive for Obgemsa(vibegron) to treat overactive bladder

Vibegron is recommended as an option for treating the symptoms of overactive bladder syndrome in adults

1 min

Drug news

NICE positive for Brukinsa(zanubrutinib) to treat marginal zone lymphoma

NICE: (UK): Zanubrutinib is recommended, within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti CD20-based treatment

1 min

See all news